Clinical Scorecard: VOY-101 Targets GA Through Complement Regulation Biology
At a Glance
| Category | Detail |
|---|---|
| Condition | Geographic Atrophy (GA) |
| Key Mechanisms | Restores complement regulation through expression of protective complement factor H protein. |
| Target Population | Patients aged 60 years or older with CFH genetic risk and GA lesion sizes ranging from 2.5 mm² to 20 mm². |
| Care Setting | Multicenter, open-label clinical trials. |
Key Highlights
- VOY-101 is a one-time intravitreal gene therapy for GA.
- Phase 1 studies showed sustained transgene expression and a well-tolerated safety profile.
- No dose-limiting toxicities or serious adverse events were reported.
- The highest dose selected for phase 2 showed 13-fold expression of protective CFHT.
- The phase 2 JOURNEY trial uses a fellow-eye control design to evaluate treatment efficacy.
Guideline-Based Recommendations
Diagnosis
- Evaluate patients for CFH genetic risk and GA lesion size.
Management
- Administer VOY-101 as a one-time intravitreal injection.
Monitoring & Follow-up
- Monitor for intraocular pressure elevation and transient mild cell observations post-treatment.
Risks
- Potential for steroid-induced intraocular pressure elevation.
Patient & Prescribing Data
Patients aged 60 years or older with geographic atrophy and CFH genetic risk.
VOY-101 provides continuous protection without the need for monthly injections.
Clinical Best Practices
- Use prophylactic steroid regimen to manage inflammation post-injection.
- Select appropriate dosing based on phase 1 study findings.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.